Effect of iron supplementation on erythropoiesis and iron-related parameters in hemodialysis patients receiving epoetin beta pegol: a randomized controlled study

Effect of iron supplementation on erythropoiesis and iron-related parameters in hemodialysis patients receiving epoetin beta pegol: a randomized controlled study - Erythropoiesis efficacy of epoetin beta pegol and timing of iron supplementation

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010084

Enrollment

200

Registered

2013-02-20

Start date

2013-02-20

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Patients treated with maintenance hemodialysis

Interventions

Iron supplementation within 2 weeks of epoetin beta pegol administration Iron supplementation after 2 weeks of epoetin beta pegol administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Patients with maintenance hemodialysis (2) Patients with renal anemia, who are treated with rHuEPO or iron

Exclusion criteria

Exclusion criteria: (1) Patients with chronic inflammation, malignant disorder, severe congestive heart failure, respiratory organs, and liver disorder (2) Patients who are receiving dialysis modalities other than hemodialysis

Design outcomes

Primary

Measure	Time frame
(1) Hemoglobin and erythropoiesis-related indexes (2)Blood chemical examination including iron-related, inflammation, nutrition indexes (3)Required dose of epoetin beta pegol (4)Hemodynamic parameters	—

Countries

Japan

Contacts

Public ContactTetsuya Fujikawa

Yokohama City University Graduate School of Medicine Department of Medical Science and Cardiorenal Medicine

tftf@yokohama-cu.ac.jp045-787-2635

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026